Key Points Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase 3 trials, and data so far are promising. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) soared to the forefront almost two years ago when it announced data on an investigational drug to serve an area of high need: weight loss. The biotech's candidate me ...